Retatrutide 10 mg

$145.00

Drug Type: Multi-Agonist Peptide (GIP, GLP-1, Glucagon Receptor Agonist)
Pharmaceutical Name: Retatrutide
Trade Name: Dragon Pharma Retatrutide
Strength: 10 mg/vial (Lab Tested: 11.046 mg/vial)
Biological Half-Life: ~6 days (Approximately 150 hours)
Liver Side Effects: Not hepatotoxic; may support liver fat reduction.
Aromatization: Does not aromatize
Recommended Dosage: Research dosing typically starts at 2-4 mg per week.
Anabolic Rate: N/A (Indirect anabolic support via improved nutrient partitioning)
Androgenic Rate: N/A
Chemical Formula: C₁₉₈H₃₀₈N₅₂O₆₅S
Chemical Molecular Mass: 4508.9 g/mol
Systematic Name: N.A. (Proprietary peptide sequence)
Package: 2 mL sealed vial (lyophilized powder)

Free worldwide shipping on all orders over $1000

  • USA Domestic: 2-5 business days
  • International: 7-14 business days
Authorized Online Store

dragonpharma.net banner

Guaranteed Safe Checkout

secure payment methods

Dragon Pharma Retatrutide 10mg peptide research vial lyophilized powder
Retatrutide 10 mg
$145.00

Dragon Pharma Retatrutide: The Next Frontier in Metabolic Research

The pursuit of an optimal physique often hinges on the ability to effectively manage body composition. While diet and exercise are foundational, cutting-edge research has opened doors to powerful compounds that can significantly influence metabolic pathways. Dragon Pharma is at the forefront of this innovation with its laboratory-tested Retatrutide 10 mg. This isn’t just another peptide; it’s a first-in-class triple-agonist that represents a monumental leap in metabolic research. Designed for serious researchers, this compound targets multiple hormonal receptors simultaneously, offering a multifaceted approach to weight management and metabolic health that was previously unimaginable.


What is Retatrutide?

Retatrutide (LY3437943) is a novel, single peptide molecule that functions as a triple agonist for three key metabolic receptors: Glucose-dependent Insulinotropic Polypeptide (GIP), Glucagon-like Peptide-1 (GLP-1), and Glucagon. This triple-action mechanism sets it apart from its predecessors, such as Semaglutide (a GLP-1 agonist) or Tirzepatide (a dual GIP and GLP-1 agonist). By engaging all three receptors, Retatrutide orchestrates a more comprehensive and potent physiological response, influencing appetite, glucose metabolism, and energy expenditure in a synergistic manner. The development of this multi-agonist peptide Retatrutide marks a significant advancement in the field of metabolic science.


How Does Dragon Pharma Retatrutide Work?

The unparalleled efficacy of Dragon Pharma’s Retatrutide stems from its unique ability to activate three separate pathways. Each receptor activation contributes a critical piece to the overall metabolic puzzle:

  • GLP-1 Receptor Agonism: Like other compounds in its class, it slows gastric emptying, promotes satiety (feelings of fullness), and stimulates glucose-dependent insulin secretion from the pancreas. This directly reduces caloric intake and improves blood sugar control.
  • GIP Receptor Agonism: GIP potentiates the release of insulin in response to food intake. Furthermore, GIP receptor activity is believed to enhance the effects of GLP-1, particularly on weight loss, and may improve fat tissue metabolism.
  • Glucagon Receptor Agonism: This is the key differentiator. Glucagon receptor activation increases energy expenditure by stimulating the liver to produce energy. It promotes lipolysis (the breakdown of fat) and increases metabolic rate, effectively helping the body burn more calories at rest. This addresses the “energy out” side of the equation, not just the “energy in.”

Benefits of Retatrutide for Body Composition Research

For bodybuilders and athletes, the cutting phase is often the most challenging part of a cycle. Retatrutide offers a powerful research tool to overcome common obstacles like hunger plateaus and metabolic adaptation.

  • Profound Appetite Suppression: The combined GLP-1 and GIP activity powerfully curbs appetite and reduces food noise, making it easier to maintain a significant caloric deficit without constant hunger. This effect can be more pronounced than with standalone GLP-1 agonists.
  • Enhanced Fat Loss: The triple-action mechanism attacks fat stores from multiple angles: reducing intake (via appetite suppression), improving nutrient partitioning, and directly increasing fat oxidation and metabolic rate through glucagon activity.
  • Improved Metabolic Parameters: Research indicates significant improvements in blood glucose levels, insulin sensitivity, and cholesterol profiles, contributing to overall health during cutting phases.
  • Muscle Sparing Potential: By providing a powerful signal for the body to use fat for fuel, there is a potential for better preservation of lean muscle mass during a caloric deficit, especially when combined with a targeted cycle of Cardarine (GW-501516) for endurance and fat oxidation.

Dragon Pharma’s Commitment to Quality: Lab-Verified Potency

Dragon Pharma Retatrutide lab test results HPLC analysis 2025
Independent Lab Verification: Potency 11.046 mg/vial (Test Date: 2025-04-22)

In the research peptide market, accuracy is everything. An under-dosed product can invalidate months of research. Dragon Pharma eliminates this uncertainty. Independent third-party laboratory testing, dated April 22, 2025, confirms that this batch of Retatrutide not only meets but exceeds its labeled potency, testing at 11.046 mg per vial against a 10 mg label claim. This commitment to transparency and overdose ensures researchers receive a product of verified quality and effectiveness, providing complete confidence in your experimental protocols.


Research Protocol and Dosage Considerations

Dragon Pharma Retatrutide 10mg is supplied as a sterile lyophilized powder for research purposes. It requires reconstitution with bacteriostatic water before subcutaneous administration. Given its long half-life of approximately 6 days, dosing is typically administered once weekly. Research protocols often initiate with a lower dose (e.g., 2-4 mg weekly) to assess tolerance, with gradual titration upwards based on observed response. The high tested potency of this vial allows for flexible and extended research cycles. Its potent effects on nutrient partitioning make it a interesting compound to study alongside traditional anabolics like Masteron (Drostanolone Propionate) for a hard, dry physique.


Potential Side Effects and Research Considerations

As a potent metabolic agent, researchers should be prepared to observe and document certain transient effects. The most commonly reported are gastrointestinal in nature, including nausea, vomiting, diarrhea, or constipation, particularly during the initial dose titration phase. These effects are typically dose-dependent and tend to subside as the research subject adapts. As with any compound affecting glucose metabolism, monitoring is advised. It is crucial to remember that this is a research compound and not approved for human consumption. For researchers focusing on insulin sensitivity, comparing notes with the effects of Metformin could provide valuable insights.

Disclaimer: This product is intended for research and laboratory use only. It is not for human or animal consumption. All information is provided for educational purposes. Please consult with a healthcare professional before considering any new research compound.


Frequently Asked Questions (Retatrutide 10mg)

How does Retatrutide compare to Semaglutide or Tirzepatide?

Retatrutide is considered a next-generation peptide. Semaglutide is a GLP-1 agonist only. Tirzepatide is a dual GIP/GLP-1 agonist. Retatrutide’s addition of glucagon receptor agonism (making it a triple agonist) appears to offer superior efficacy in clinical research settings for both weight loss and metabolic improvement, primarily by increasing energy expenditure.

What does the lab test result of 11.046 mg mean?

It means an independent lab analysis confirmed that the vial contains more peptide than advertised. While labeled as 10 mg, the actual content is 11.046 mg. This “overdose” is a mark of quality and integrity, ensuring researchers receive full value and can trust the product’s potency for their studies.

How should Retatrutide be stored?

Unreconstituted (lyophilized powder) vials should be stored refrigerated or frozen for long-term stability. Once reconstituted with bacteriostatic water, the solution must be refrigerated and is typically stable for several weeks. Always use sterile techniques.

Is Retatrutide suitable for long-term research cycles?

Due to its long half-life of ~6 days, it is well-suited for longer-term metabolic studies. However, as with any potent compound, protocols should include periods of observation off the compound to assess long-term effects and sustainability of results.

Additional information

Brand

Dragon Pharma

Active Ingredient

Retatrutide

Strength

10 mg/vial

Form

Lyophilized Powder

Product Type

GIP, GLP-1, Glucagon Receptor Agonist

Reviews

There are no reviews yet.

Be the first to review “Retatrutide 10 mg”

Your email address will not be published. Required fields are marked *